clinical trial · NCT07196722
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase3·recruiting·n = 1,092
Crohn DiseaseIcotrokinraPlacebo
brief summary
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
started
Oct 3, 2025
primary completion
Sep 19, 2028
completion
Oct 6, 2032
last updated
Mar 12, 2026
official title
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol